Molecular analysis for refractory rare cancers: Sequencing battle continues – learnings for the MOSCATO-01 study-Reference-Cited by-同舟云学术

Molecular analysis for refractory rare cancers: Sequencing battle continues – learnings for the MOSCATO-01 study

Published:2023-01 Issue: Volume:181 Page:103888
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Debien Véronique,Vignot Stéphane,Massard Christophe,Malouf Gabriel,Hollebecque Antoine,Scoazec Jean-Yves,Michiels Stefan,Verlingue Loïc

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference36 articles.

1. Phase I trials as valid therapeutic options for patients with cancer;Adashek;Nat. Rev. Clin. Oncol.,2019

2. Overcoming resistance to tumor-targeted and immune-targeted therapies;Aldea;Cancer Discov.,2021

3. ANSM_compassionate use programs [WWW Document], n.d. URL 〈https://ansm.sante.fr/documents/reference/referentiel-des-specialites-en-acces-derogatoire〉).

4. Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM);Bayle;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2022

5. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial;Chiba;BMC Cancer,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST;Acta Oncologica;2024-05-28

2. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution;International Journal of Molecular Sciences;2024-04-07

3. Patients’ selection and trial matching in early-phase oncology clinical trials;Critical Reviews in Oncology/Hematology;2024-04

4. Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial;International Journal of Clinical Oncology;2023-12-19

5. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis;European Journal of Cancer;2023-09